Trial Profile
Phase 2 Study of Daratumumab in Combination With Thalidomide and Dexamethasone in Relapse and / or Refractory Myeloma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 12 Dec 2023 Results (n=70, median age 66.8 (range 39 -81)) assessing effectiveness of combination of daratumumab, thalidomide and dexamethasone, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 08 Dec 2020 Interim results (n=36; Data cutoff date: 23 Jun 2020) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 05 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.